MedTrace Logo

Bioequivalence Study of Two Strengths of Two Different Metformin Tablets Administered to Healthy Male and Female Subjects

NCT02183571 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 56

Last updated 2014-07-08

No results posted yet for this study

Summary

Investigation of bioequivalence of BMS Glucophage® tablets and Merck Glucophage® tablets in the strengths of 1000 mg (part I) and 500 mg (part II)

Conditions

  • Healthy

Interventions

DRUG

Merck Glucophage® high dose

Part I: Treatment A

DRUG

BMS Glucophage® high dose

Part I: Treatment B

DRUG

Merck Glucophage® low dose

Part II: Treatment C

DRUG

BMS Glucophage® low dose

Part II: Treatment D

Sponsors & Collaborators

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-02-28
Primary Completion
2009-04-30

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02183571 on ClinicalTrials.gov